phrykt

Halozyme Therapeutics, Inc. (HALO): who owns it and who trades it

As of Nov 16, 2026, HALO insiders reported 106 open-market sales worth $49.8M and no purchases in the last 12 months, with 96% of the sale value made under pre-set 10b5-1 plans. The largest seller was Helen Torley (CEO), with $44M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Halozyme Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and Congress mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns HALO

666 funds and institutions reported HALO shares worth $9.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 11.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.11.2%
Vanguard Capital Management LLC4.5%
Vanguard Portfolio Management LLC4.5%
State Street Corp4.4%
Invesco Ltd.2.7%
Morgan Stanley2.4%
Boston Partners2.3%
Bank of America Corp2.3%
Geode Capital Management, LLC2.1%
William Blair Investment Management, LLC2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.13.27M11.19%$1BNo change
Vanguard Capital Management LLC5.35M4.51%$419M+2%
Vanguard Portfolio Management LLC5.30M4.47%$415M+1%
State Street Corp5.18M4.37%$405M+5%
Invesco Ltd.3.18M2.68%$249M-21%
Morgan Stanley2.83M2.39%$222M+11%
Boston Partners2.77M2.34%$217M+3%
Bank of America Corp2.74M2.31%$215M-6%
Geode Capital Management, LLC2.52M2.12%$197M+1%
William Blair Investment Management, LLC2.51M2.12%$197M-1%
Snyder Capital Management L P2.40M2.02%$188M+3%
Dimensional Fund Advisors LP2.09M1.76%$164M+0%
D. E. Shaw & Co., Inc.2.01M1.69%$157M+7%
Assenagon Asset Management S.A.2.00M1.68%$156M–
Los Angeles Capital Management LLC1.94M1.63%$152M+181%
Royal London Asset Management Ltd1.81M1.53%$142M+12%
Arrowstreet Capital, Limited Partnership1.70M1.44%$133M-11%
Alliancebernstein L.P.1.70M1.43%$110M-2%
Two Sigma Investments, LP1.65M1.39%$129M+4%
UBS Group AG1.49M1.26%$117M+63%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, HALO insiders reported $0 of open-market purchases and $49.8M of sales. 96% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$49.8M
106 trades, 5 people
Sales under a 10b5-1 plan
96%
Share of sale value
Latest trade
Nov 16, 2026
Filed Nov 16, 2026

Purchases and sales by month

$8.5M$8.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 16, 2026Helen TorleyCEOSale plan7,283$96.85$705KForm 4
Nov 16, 2026Helen TorleyCEOSale plan4,802$97.95$470KForm 4
Nov 16, 2026Helen TorleyCEOSale plan1,586$98.89$157KForm 4
Nov 16, 2026Helen TorleyCEOSale plan4,897$100.10$490KForm 4
Nov 16, 2026Helen TorleyCEOSale plan1,244$101.06$126KForm 4
Nov 16, 2026Helen TorleyCEOSale plan188$101.72$19.1KForm 4
Nov 13, 2026Helen TorleyCEOSale plan7,992$100.02$799KForm 4
Nov 13, 2026Helen TorleyCEOSale plan12,008$100.61$1.2MForm 4
Nov 12, 2026Helen TorleyCEOSale plan10,711$101.09$1.1MForm 4
Nov 12, 2026Helen TorleyCEOSale plan9,289$101.49$943KForm 4
Oct 8, 2026Helen TorleyCEOSale plan4,810$108.18$520KForm 4
Oct 8, 2026Helen TorleyCEOSale plan3,090$108.91$337KForm 4
Oct 8, 2026Helen TorleyCEOSale plan11,900$110.00$1.3MForm 4
Oct 8, 2026Helen TorleyCEOSale plan200$110.51$22.1KForm 4
Oct 7, 2026Helen TorleyCEOSale plan8,600$111.03$955KForm 4
Oct 7, 2026Helen TorleyCEOSale plan10,300$111.84$1.2MForm 4
Oct 7, 2026Helen TorleyCEOSale plan900$112.78$102KForm 4
Oct 7, 2026Helen TorleyCEOSale plan200$113.69$22.7KForm 4
Oct 6, 2026Helen TorleyCEOSale plan2,300$107.90$248KForm 4
Oct 6, 2026Helen TorleyCEOSale plan6,000$109.33$656KForm 4
Oct 6, 2026Helen TorleyCEOSale plan9,920$109.89$1.1MForm 4
Oct 6, 2026Helen TorleyCEOSale plan1,780$110.81$197KForm 4
Oct 1, 2026Matthew L. PosardDirectorSale plan730$107.17$78.2KForm 4
Oct 1, 2026Matthew L. PosardDirectorSale plan3,300$108.45$358KForm 4
Oct 1, 2026Matthew L. PosardDirectorSale plan1,100$109.57$121KForm 4
Oct 1, 2026Matthew L. PosardDirectorSale plan100$110.04$11KForm 4
Sep 16, 2026Matthew L. PosardDirectorSale plan3,000$106.83$320KForm 4
Sep 16, 2026Matthew L. PosardDirectorSale plan8,896$108.04$961KForm 4
Sep 16, 2026Matthew L. PosardDirectorSale plan3,100$106.13$329KForm 4
Sep 16, 2026Matthew L. PosardDirectorSale plan4,000$108.99$436KForm 4
Sep 11, 2026Helen TorleyCEOSale plan4,508$107.55$485KForm 4
Sep 11, 2026Helen TorleyCEOSale plan15,492$107.15$1.7MForm 4
Sep 10, 2026Helen TorleyCEOSale plan14,588$107.01$1.6MForm 4
Sep 10, 2026Helen TorleyCEOSale plan5,412$107.58$582KForm 4
Sep 9, 2026Helen TorleyCEOSale plan100$108.67$10.9KForm 4
Sep 9, 2026Helen TorleyCEOSale plan6,596$107.82$711KForm 4
Sep 9, 2026Helen TorleyCEOSale plan13,304$107.22$1.4MForm 4
Aug 19, 2026Helen TorleyCEOSale plan7,200$106.36$766KForm 4
Aug 19, 2026Helen TorleyCEOSale plan9,600$107.22$1MForm 4
Aug 19, 2026Helen TorleyCEOSale plan3,200$107.77$345KForm 4
Aug 18, 2026Helen TorleyCEOSale plan5,703$103.08$588KForm 4
Aug 18, 2026Helen TorleyCEOSale plan4,897$104.11$510KForm 4
Aug 18, 2026Helen TorleyCEOSale plan9,400$104.87$986KForm 4
Aug 17, 2026Helen TorleyCEOSale plan7,500$103.48$776KForm 4
Aug 17, 2026Helen TorleyCEOSale plan9,000$102.55$923KForm 4
Aug 17, 2026Helen TorleyCEOSale plan2,100$101.77$214KForm 4
Aug 17, 2026Helen TorleyCEOSale plan500$100.46$50.2KForm 4
Aug 17, 2026Helen TorleyCEOSale plan900$98.96$89.1KForm 4
Aug 10, 2026Bernadette ConnaughtonDirectorSale plan1,626$102.80$167KForm 4
Jul 8, 2026Helen TorleyCEOSale plan888$79.28$70.4KForm 4
Jul 8, 2026Helen TorleyCEOSale plan1,035$80.19$83KForm 4
Jul 1, 2026Bernadette ConnaughtonDirectorSale plan625$77.21$48.3KForm 4
Jul 1, 2026Bernadette ConnaughtonDirectorSale plan1,000$76.40$76.4KForm 4
Jun 29, 2026Mahesh KrishnanDirectorSale plan7,304$75.00$548KForm 4
Jun 3, 2026Helen TorleyCEOSale plan6,100$69.69$425KForm 4
Jun 3, 2026Helen TorleyCEOSale plan400$66.37$26.5KForm 4
Jun 3, 2026Helen TorleyCEOSale plan1,500$67.68$102KForm 4
Jun 3, 2026Helen TorleyCEOSale plan2,000$68.74$137KForm 4
Jun 2, 2026Helen TorleyCEOSale plan3,400$66.75$227KForm 4
Jun 2, 2026Helen TorleyCEOSale plan16,600$66.31$1.1MForm 4
Jun 1, 2026Helen TorleyCEOSale plan1,610$66.39$107KForm 4
Jun 1, 2026Helen TorleyCEOSale plan12,989$67.41$876KForm 4
Jun 1, 2026Helen TorleyCEOSale plan5,401$68.35$369KForm 4
Jun 1, 2026Bernadette ConnaughtonDirectorSale plan1,625$66.21$108KForm 4
May 13, 2026Helen TorleyCEOSale plan2,100$68.10$143KForm 4
May 13, 2026Helen TorleyCEOSale plan3,350$68.88$231KForm 4
May 13, 2026Helen TorleyCEOSale plan3,950$69.79$276KForm 4
May 13, 2026Helen TorleyCEOSale plan600$70.81$42.5KForm 4
May 12, 2026Helen TorleyCEOSale plan2,800$73.12$205KForm 4
May 12, 2026Helen TorleyCEOSale plan100$67.85$6.8KForm 4
May 12, 2026Helen TorleyCEOSale plan1,398$70.29$98.3KForm 4
May 12, 2026Helen TorleyCEOSale plan9,802$71.37$700KForm 4
May 12, 2026Helen TorleyCEOSale plan5,900$72.15$426KForm 4
May 11, 2026Helen TorleyCEOSale plan9,725$64.63$629KForm 4
May 11, 2026Helen TorleyCEOSale plan3,575$65.46$234KForm 4
May 11, 2026Helen TorleyCEOSale plan6,700$66.33$444KForm 4
May 1, 2026Bernadette ConnaughtonDirectorSale plan1,625$63.48$103KForm 4
Apr 6, 2026Helen TorleyCEOSale plan5,900$63.14$373KForm 4
Apr 6, 2026Helen TorleyCEOSale plan4,100$64.02$262KForm 4
Apr 2, 2026Helen TorleyCEOSale plan4,200$64.89$273KForm 4
Apr 2, 2026Helen TorleyCEOSale plan15,800$64.06$1MForm 4
Apr 1, 2026Helen TorleyCEOSale plan19,000$65.36$1.2MForm 4
Apr 1, 2026Helen TorleyCEOSale plan1,000$65.71$65.7KForm 4
Mar 10, 2026Cortney CaudillVice presidentSale8,857$67.64$599KForm 4
Mar 9, 2026Cortney CaudillVice presidentSale2,100$68.25$143KForm 4
Mar 9, 2026Cortney CaudillVice presidentSale17,900$67.75$1.2MForm 4
Mar 4, 2026Helen TorleyCEOSale plan7,329$69.94$513KForm 4
Mar 4, 2026Helen TorleyCEOSale plan2,671$70.95$190KForm 4
Mar 3, 2026Helen TorleyCEOSale plan13,481$68.85$928KForm 4
Mar 3, 2026Helen TorleyCEOSale plan6,519$69.33$452KForm 4
Mar 2, 2026Helen TorleyCEOSale plan4,100$69.20$284KForm 4
Mar 2, 2026Helen TorleyCEOSale plan15,322$69.80$1.1MForm 4
Mar 2, 2026Helen TorleyCEOSale plan578$70.46$40.7KForm 4
Feb 5, 2026Helen TorleyCEOSale plan5,376$78.38$421KForm 4
Feb 5, 2026Helen TorleyCEOSale plan4,624$78.94$365KForm 4
Feb 4, 2026Helen TorleyCEOSale plan10,100$77.54$783KForm 4
Feb 4, 2026Helen TorleyCEOSale plan9,900$76.94$762KForm 4
Feb 3, 2026Helen TorleyCEOSale plan2,551$74.88$191KForm 4
Feb 3, 2026Helen TorleyCEOSale plan9,659$75.94$734KForm 4
Feb 3, 2026Helen TorleyCEOSale plan7,790$76.73$598KForm 4

Latest 100 of 106 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Helen TorleyPRESIDENT AND CEO, Director–$44MNov 16, 2026
Matthew L. PosardDirector–$2.6MOct 1, 2026
Cortney CaudillSVP, CHIEF OPERATING OFFICER–$2MMar 10, 2026
Bernadette ConnaughtonDirector–$702KAug 10, 2026
Mahesh KrishnanDirector–$548KJun 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HALO short interest

High short interest. 12.0% of HALO shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 2%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 13.65M HALO shares were sold short, 12.0% of the shares outstanding, unchanged from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 6.8 trading days (days to cover).

Shares short, % of all shares

12.0%May 15Oct 3013.9%

Days to cover

6.8May 15Oct 3012.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202613.65M12.03%No change2.01M6.8
Oct 15, 202613.65M12.03%-11%2.22M6.2
Sep 30, 202615.30M13.48%+1%3.37M4.5
Sep 15, 202615.15M13.35%+2%1.31M11.6
Aug 31, 202614.88M13.11%+2%1.71M8.7
Aug 14, 202614.64M12.90%+4%2.92M5.0
Jul 31, 202614.02M12.35%+5%1.68M8.3
Jul 15, 202613.30M11.21%+1%1.83M7.3
Jun 30, 202613.23M11.15%+2%2.11M6.3
Jun 15, 202612.95M10.92%-5%1.65M7.8
May 29, 202613.64M11.50%+2%1.68M8.1
May 15, 202613.39M11.29%-7%1.99M6.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded HALO

Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 2 sales of HALO. The latest was a sale by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.

Purchases 1Sales 2

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfOct 12, 2026Report
Mar 9, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Mar 24, 2025Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfApr 7, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Halozyme Therapeutics company events

Halozyme Therapeutics filed 18 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 30, 2026LeadershipJames Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. Filing
  3. Sep 22, 2026AgreementHalozyme Therapeutics, Inc. completed its previously announced sale of $1,500.0 million of 1.50% Convertible Senior Notes due 2033, including $200.0 million in of its Convertible Notes purchased pursuant to the exercise by the initial purchasers of the Convertible Notes of the option to purchase… Filing
  4. Sep 18, 2026AnnouncementHalozyme Therapeutics, Inc. issued a press release announcing the pricing of its offering of $1.3 billion of convertible senior notes due 2033. Filing
  5. Sep 16, 2026AnnouncementHalozyme Therapeutics, Inc. issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $1.05 billion of convertible senior notes due 2033. Filing
  6. Aug 18, 2026LeadershipDannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. Filing
  7. Aug 6, 2026ResultsReleased financial results. Filing
  8. Jul 2, 2026LeadershipHalozyme Therapeutics, Inc. announced an update to its senior management structure. Filing
  9. May 11, 2026ResultsReleased financial results. Filing
  10. May 7, 2026VoteReported shareholder vote results. Filing
  11. Apr 30, 2026LeadershipHalozyme Therapeutics, Inc. announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer, effective June 8, 2026. Filing
  12. Apr 24, 2026RulesChanged its bylaws or articles. Filing
  13. Mar 12, 2026LeadershipHalozyme Therapeutics, Inc. announced that David Ramsay has been appointed to serve as the Company’s Interim Chief Financial Officer, effective March 23, 2026. Filing
  14. Feb 17, 2026ResultsReleased financial results. Filing
  15. Jan 28, 2026ResultsReleased financial results. Filing
  16. Dec 9, 2025LeadershipThe Compensation Committee of the Board of Directors of Halozyme Therapeutics, Inc. approved a performance-based restricted stock unit grant for Dr. Helen Torley, Chief Executive Officer of the Company. Filing
  17. Dec 8, 2025LeadershipJames Lang was elected to the Board of Directors of Halozyme Therapeutics, Inc. Filing
  18. Nov 24, 2025LeadershipAs previously disclosed, Halozyme Therapeutics, Inc. announced a transition plan in which Nicole LaBrosse, Senior Vice President, Chief Financial Officer will continue to serve as the Company’s Chief Financial Officer until the earliest of when a new chief financial officer is hired, March 30, 2026… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Halozyme Therapeutics financials

Famous investors that hold HALO

5 of the 50 well-known investors we track reported holding HALO in their latest 13F filing. The largest position is Ken Griffin's, worth $66.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026598,639$66.1M0.0%+107%
Jim Simons · Renaissance TechnologiesQ3 2026598,111$66M0.1%+25%
Ray Dalio · Bridgewater AssociatesQ3 2026328,269$36.2M0.2%-29%
Israel Englander · Millennium ManagementQ3 2026198,321$21.9M0.0%+899%
George Soros · Soros Fund ManagementQ3 202664,118$7.1M0.1%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Halozyme Therapeutics, Inc. (HALO) stock

Who owns the most HALO stock?

The largest reported owner of Halozyme Therapeutics, Inc. (HALO) is BlackRock, Inc., with 11.2% of the company. In total, 666 funds and institutions reported holding HALO at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are HALO insiders buying or selling?

In the last 12 months, HALO insiders reported no open-market purchases and 106 sales worth $49.8M. The latest trade was on Nov 16, 2026. See every trade.

What is the short interest in HALO?

As of Oct 30, 2026, 13.65M HALO shares were sold short, 12.0% of the shares outstanding, unchanged from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 6.8 trading days (days to cover). See the history.

Have members of Congress traded HALO?

Yes. 1 member of Congress reported 1 purchase and 2 sales of HALO since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.

Which famous investors hold HALO?

5 of the 50 well-known investors we track reported HALO in their latest 13F filing, including Ken Griffin, Jim Simons, Ray Dalio. The largest position is worth $66.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.